Combination of Asciminib plus Nilotinib or Asciminib plus Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results

被引：4

作者：

DeAngelo, Daniel J. ^{[1
]}

Mauro, Michael J. ^{[2
]}

Kim, Dong-Wook ^{[3
]}

Cortes, Jorge ^{[4
]}

Rea, Delphine ^{[5
]}

Hughes, Timothy P. ^{[6
,7
]}

Minami, Hironobu ^{[8
]}

Breccia, Massimo ^{[9
]}

Talpaz, Moshe ^{[10
]}

Hochhaus, Andreas ^{[11
]}

Goh, Yeow Tee ^{[12
]}

Le Coutre, Philipp D. ^{[13
]}

Sondhi, Manu ^{[14
]}

Mishra, Kaushal ^{[14
]}

Hourcade-Potelleret, Florence ^{[15
]}

Vanasse, Gary ^{[15
]}

Aimone, Paola ^{[15
]}

Lang, Fabian ^{[16
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Catholic Univ Korea, Seoul St Marys Hosp, Leukemia Res Inst, Seoul, South Korea

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Hop St Louis, Paris, France

[6] SA Pathol, Adelaide, SA, Australia

[7] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[8] Kobe Univ Hosp, Kobe, Hyogo, Japan

[9] Univ Roma La Sapienza, Rome, Italy

[10] Univ Michigan, Ann Arbor, MI 48109 USA

[11] Univ Klinikum Jena, Abt Hamatol Onkol, Jena, Germany

[12] Singapore Gen Hosp, Singapore, Singapore

[13] Charite Univ Med Berlin, Berlin, Germany

[14] Novartis Pharmaceut, E Hanover, NJ USA

[15] Novartis Pharma AG, Basel, Switzerland

[16] Goethe Univ Frankfurt Main, Frankfurt, Germany

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷

关键词：

asciminib; tyrosine kinase inhibitor; clinical trial; CML; chronic myelogenous leukemia;

D O I：

10.1016/j.clml.2019.07.236

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-102

引用

页码：S290 / S291

页数：3

共 50 条

[1] Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results
Talpaz, Moshe
Cortes, Jorge
Lang, Fabian
Kim, Dong-Wook
Rea, Delphine
Mauro, Michael J.
Minami, Hironobu
Breccia, Massimo
DeAngelo, Daniel J.
Hochhaus, Andreas
Goh, Yeow Tee
Le Coutre, Philipp D.
Sondhi, Manu
Mishra, Kaushal
Hourcade-Potelleret, Florence
Vanasse, Gary
Aimone, Paola
Hughes, Timothy P.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S287 - S288
[2] Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia ChromosomePositive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph plus CMLCP/AP): Final Results from the Asciminib Phase 1 Study
Cortes, Jorge
Lang, Fabian
Rea, Delphine
Hochhaus, Andreas
Breccia, Massimo
Goh, Yeow Tee
Heinrich, Michael C.
Hughes, Timothy P.
Janssen, Jeroen J. W. M.
Le Coutre, Philipp
Minami, Hironobu
Sasaki, Koji
DeAngelo, Daniel J.
Sanchez-Olle, Gessami
Pognan, Nathalie
Jose, Jomy
Hoch, Matthias
Mauro, Michael
BLOOD, 2023, 142
[3] Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML)
Mauro, Michael J.
Lang, Fabian
Kim, Dong-Wook
Cortes, Jorge E.
Hughes, Timothy P.
Hochhaus, Andreas
Minami, Hironobu
Boquimpani, Carla
Minami, Yosuke
Breccia, Massimo
Goh, Yeow-Tee
Ottmann, Oliver
Sondhi, Manu
Hois, Stephan
Bedoucha, Veronique
Perraud, Kevin
Rea, Delphine
DeAngelo, Daniel J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S223 - S223
[4] Platelet function in patients with chronic myeloid leukemia treated with asciminib
Nesr, George
Laffan, Mike
Claudiani, Simone
Innes, Andrew
Apperley, Jane
Milojkovic, Dragana
LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 3021 - 3023
[5] An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors
Garcia-Gutierrez, Valentin
Carlos Hernandez-Boluda, Juan
EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (06) : 477 - 484
[6] Frontline Asciminib Combination in Chronic Phase Chronic Myeloid Leukemia Patients. The FASCINATION Trial
Ernst, T.
Le Coutre, P.
Crysandt, M.
Bruemmendorf, T. H.
Franke, G. -N.
Illmer, T.
Burchert, A.
Lang, F.
Saussele, S.
Teichmann, L.
Radsak, M. P.
Krause, S. W.
Rinke, J.
Fabisch, C.
Lang, T.
Pfirrmann, M.
Hochhaus, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 67 - 67
[7] Calr plus Myelofibrosis/BCR-ABL Chronic Myeloid Leukemia Overlap Syndrome Treated with Asciminib
Saal, Talia M.
Pellegrino, Christine
Ahmed, Tauseef
Seiter, Karen
Liu, Delong
Steinberg, Amir
BLOOD, 2023, 142
[8] A Multicenter, Randomized Phase 3 Study of Asciminib (ABL001) vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 TKIs
Mauro, Michael J.
Hochhaus, Andreas
Boquimpani, Carla
Minami, Yosuke
Allepuz, Alex
Polydoros, Fotis
Bedoucha, Veronique
Aimone, Paola
Rea, Delphine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S286 - S287
[9] The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
Martinez-Lopez, Joaquin
Mustjoki, Satu
Porkka, Kimmo
Klisovic, Rebecca B.
Wolf, Dominik
Busque, Lambert
Hernandez-Boluda, Juan Carlos
Swanink, Rene
Martin Regueira, Patricia
Lipton, Jeffrey H.
LEUKEMIA & LYMPHOMA, 2021, 62 (08) : 2040 - 2043
[10] Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations
Andorsky, David
Tomassetti, Sarah
Deutsch, Yehuda E.
Broun, E. Randolph
Issa, Ghayas C.
Levy, Moshe Y.
Deininger, Michael W.
Maegawa, Rodrigo
Shrestha, Alok
Mauro, Michael J.
BLOOD, 2021, 138

← 1 2 3 4 5 →